Compare Regeneron Pharmaceuticals Inc (REGN) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while Vanguard Intermediate Term Corporate Bond ETF trades at $80.48. The key difference: Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Vanguard Intermediate Term Corporate Bond ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| REGN | VCIT | |
|---|---|---|
Market Cap | $83.43B | — |
Sector | Health | Fixed Income |
52-Week High | $852.03 | $84.82 |
52-Week Low | $555.51 | $80.31 |
Enterprise Value | $78.14B | — |
Dividend Yield | 0.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
VCIT trades at $80.46, down 0.09% on the day, with a bearish technical signal from moving averages but bullish oscillators. The ETF offers a 4.8% yield and low 0.03% expense ratio, attracting institutional interest as seen with HB Wealth Management increasing holdings by 242.9% in Q3 2026 (SEC filing, September 2026). Recent news highlights its competitive edge in intermediate-term corporate bonds.
The outlook remains favorable for income investors seeking yield with moderate risk, though bearish momentum and interest rate sensitivity pose near-term headwinds. Key opportunities include cost efficiency and diversification, while risks involve market volatility and economic shifts affecting corporate credit.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
